What is your preferred regimen for treating pediatric patients with intermediate risk Hodgkin lymphoma: AHOD0031 or POG9425?  

AHOD0031 may avoid radiation; however, has potential for more chemotherapy toxicity.  On POG9425 everyone receives radiation; however, patients may have less toxicity from chemotherapy.  How do you weigh the risk vs benefit of each regimen?